Development of Chemokines for Myeloprotection

We will develop a myelostatic agent to protect human hematopoietic precursor cells from the destrucchemotherapeutic agents currently used in the treatment of tumors. We propose that protection of preinhibition of growth during cancer treatment would reduce the toxicity associated with standard chemadministration of higher doses of chemotherapeutics without compromising the ability of the patientfunctional blood cells. They have identified a family of novel chemokine-based agents, which reversicell proliferation in vitro at very low concentrations. Their initial plan is to test the agents' efproliferation of murine hematopoietic progenitor cells in vivo. Successful completion of this goal mclinical candidate. In parallel, we will express, purify, and test in an in vitro stem cell proliferagents. The hypothesis is that the determination of the protein domains within the chemokine proteinbiological activity will lead to peptide mimetics or small organic molecule drug candidates for evaland in vivo assays to assess their clinical potential.